Khalid Eljaaly
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria
Papers in
-
- COVID-19 Clinical Research Studies 7
- Antimicrobial Resistance in Staphylococcus 5
- Pharmacology 15
- Antibiotics Pharmacokinetics and Efficacy 11
- Co-authors
- Samah Alshehri (14 shared papers)Jaffar A. Al‐Tawfiq (7 shared papers)Jessica K. Ortwine (3 shared papers)Aisha Alharbi (6 shared papers)Abrar K. Thabit (17 shared papers)Jason M. Pogue (1 shared paper)Mushira A. Enani (2 shared papers)Tarek S. Ibrahim (5 shared papers)
- Journals
- Saudi Pharmaceutical Journal (6 papers)Journal of Infection and Public Health (4 papers)International Journal of Infectious Diseases (3 papers)BMC Infectious Diseases (3 papers)Antibiotics (3 papers)
- Partner nations
- Saudi ArabiaUnited StatesEgypt
In The Last Decade
Khalid Eljaaly
72 papers receiving 1000 citations
Peers
Comparison fields: 5 of 111
- Applied Microbiology and Biotechnology 141
- Molecular Medicine 237
- Geriatrics and Gerontology 60
- Infectious Diseases 181
- Pharmacology 144
Countries citing papers authored by Khalid Eljaaly
This map shows the geographic impact of Khalid Eljaaly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Eljaaly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Eljaaly more than expected).
Fields of papers citing papers by Khalid Eljaaly
This network shows the impact of papers produced by Khalid Eljaaly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Eljaaly. The network helps show where Khalid Eljaaly may publish in the future.
Co-authors
The 25 scholars most cited alongside Khalid Eljaaly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 84 | |
| 2 | 2020 | 68 | |
| 3 | 2021 | 68 | |
| 4 | 2021 | 53 | |
| 5 | 2018 | 41 | |
| 6 | 2021 | 35 | |
| 7 | 2022 | 35 | |
| 8 | 2021 | 34 | |
| 9 | 2017 | 31 | |
| 10 | 2022 | 28 | |
| 11 | 2018 | 27 | |
| 12 | 2021 | 25 | |
| 13 | 2022 | 23 | |
| 14 | 2018 | 23 | |
| 15 | 2022 | 22 | |
| 16 | 2019 | 22 | |
| 17 | 2021 | 21 | |
| 18 | 2020 | 21 | |
| 19 | 2021 | 18 | |
| 20 | 2021 | 18 |
About Khalid Eljaaly
Khalid Eljaaly is a scholar working on Infectious Diseases, Pharmacology, Applied Microbiology and Biotechnology, Epidemiology and Molecular Medicine, having authored 76 papers that have together received 1.0k indexed citations. Recurring topics across this work include Antibiotic Use and Resistance (15 papers), Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers), Pneumonia and Respiratory Infections (8 papers), COVID-19 Clinical Research Studies (7 papers), Pharmaceutical Practices and Patient Outcomes (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (4 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (141 citations), Molecular Medicine (237 citations), Geriatrics and Gerontology (60 citations), Infectious Diseases (181 citations) and Pharmacology (144 citations). Khalid Eljaaly has collaborated with scholars based in Saudi Arabia, United States and Egypt. Frequent co-authors include Samah Alshehri, Jaffar A. Al‐Tawfiq, Jessica K. Ortwine, Aisha Alharbi, Abrar K. Thabit, Jason M. Pogue, Mushira A. Enani, Tarek S. Ibrahim, Brian L. Erstad and Nabil A. Alhakamy. Their work appears in journals such as Saudi Pharmaceutical Journal, Journal of Infection and Public Health, International Journal of Infectious Diseases, BMC Infectious Diseases and Antibiotics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.